Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 21, 2026

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

View original at finance.yahoo.com
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk Novo Nordisk NVO and Eli Lilly LLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GLP-1 therapy sales (Mounjaro and Zepbound) are expected to remain strong throughout 2026

    60% confidence

  • Early launch data for Foundayo has been encouraging, and insurance coverage for the pill is expanding rapidly through major pharmacy benefit managers

    60% confidence

  • Lilly expects to launch Foundayo in most international markets during 2027

    60% confidence

Data points we hold from this source

Novo Nordisk · market share94 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk — Source | Via News | ViaNews Market